5-HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner

Brain Research

Volumn 947, Issue 2, 2002, Pages 157-165

  Liégeois, Jean François ^b   Ichikawa, Junji ^a   Meltzer, Herbert Y ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Catecholamine release

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; SEROTONIN 2A ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN REGION; CALCULATION; CONTROLLED STUDY; DOPAMINE RELEASE; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY;

ANIMALS; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXTRACELLULAR SPACE; FLUOROBENZENES; HALOPERIDOL; MALE; MICRODIALYSIS; NUCLEUS ACCUMBENS; PIPERIDINES; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0037199768     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)02620-3     Document Type: Article

References (67)

1. Increased striatal dopamine transmission in schizophrenia: Confiramation in a second cohort
2. 2 receptors by dopamine in schizophrenia
3. 2 receptors: An autoradiographic analysis in rat brain
4. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system
5. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex
6. Catecholamine modulation of prefrontal cortical cognitive function
7. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
8. 2A/2C receptor antagonist, potentiates haloperidol induced dopamine release in the medial prefrontal cortex and nucleus accumbens
9. 123I-IBZM single photon emission tomography (SPET) study
10. Increase of dialysate dopamine in the bed nucleus of stria terminalis by clozapine and related neuroleptics
11. 2 receptor occupancy?
12. Dopamine in schizophrenia: A review and reconceptualization
13. 2B/2C receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation
14. 3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons
15. 2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system
16. Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia
17. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs
18. 2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine-relation to extrapyramidal side effects
19. 2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats
20. 2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat
21. 2 adrenoceptor blockade
22. 2C/2A receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum
23. 1A receptor agonist, potentiated S-(-) sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum
24. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs
25. 1A receptors on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens
26. 1A receptor activation: A possible mechanism of atypical antipsychotic-induced cortical dopamine release
27. 1A receptors mediate inhibition of tyrosine hydroxylation in rat striatum
28. 1A receptor agonists buspirone, ipsapirone and gepirone are inhibitors of tyrosine hydroxylation in rat striatum
29. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A PET study
30. 2 antagonism and EPS benefits: Is there a causal connection?
31. Serotonin-dopamine interaction and its relevance to schizophrenia
32. 3H-raclopride reveals much higher occupancy than EEDQ
33. 2 receptor occupancy
34. 2 receptor explain the action of atypical antipsychotics?: A new hypothesis
35. Dopamine, the prefrontal cortex and schizophrenia
36. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens
37. 1A receptor agonist, attenuated amphetamine-induced dopamine synthesis in rat striatum, but not nucleus accumbens or medial prefrontal cortex
38. Increased dopamine transmission in schizophrenia: Relationship to illness phases
39. 2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum
40. 2C receptor subtypes and significance of the haloperidol dose used
41. Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens
42. 2 receptor occupancy by typical and atypical antipsychotic drugs in vivo
43. The dopamine hypothesis of schizophrenia: A review
44. i values
45. The role of serotonin in antipsychotic drug action
46. 2 receptor occupancy and the action of clozapine: Does it make a difference to add a neuroleptic?
47. The effect of clozapine, risperidone and olanzapine on cognitive function in schizophrenia
48. An atypical compound by any other name is still atypical
49. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study
50. 2A receptor occupancy in schizophrenic patients
51. Novel antipsychotic agents with dopamine autoreceptor agonist properties: Synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives
52. 2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex
53. 2 receptor occupancy in patients treated with olanzapine
54. 2 binding affinity
55. 1C receptors
56. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
57. 2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
58. 2C receptors subtypes in the control of haloperidol-induced release of dopamine in the rat striatum
59. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors
60. 2 receptor binding study of risperidone and haloperidol
61. 11C]raclopride?: PET studies combined with microdialysis in conscious monkeys
62. 2 receptor blocking agent, ritanserin, in the rat
63. Enhancement of antipsychotic-like properties of raclopride in rats using the selective serotonin2a receptor antagonist MDL 100,907
64. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum
65. Inhibitory effect of haloperidol on evoked dopamine release from striatal slices of the rat
66. Differential effects of dopamine antagonists on evoked dopamine release from slices of striatum and nucleus accumbens in rats